| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | | | | | | | | | | | | | Cost of sales | | Other expense (income), net | | Cost of sales | | Other expense (income), net | | | | | | (Millions) | | 2024 | | 2023 | | 2024 | | 2023 | | 2024 | | 2023 | | 2024 | | 2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total consolidated financial statement line item amount | | $ | 3,647 | | | $ | 3,716 | | | $ | (405) | | | $ | 206 | | | $ | 10,703 | | | $ | 11,188 | | | $ | (323) | | | $ | 334 | | | | | | | | | | | | | | Pre-tax amounts recognized in income related to derivative instruments | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Information regarding cash flow and fair value hedging relationships: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (Gain) or loss on cash flow hedging relationships: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Foreign currency forward/option contracts: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income* | | (23) | | | (40) | | | — | | | — | | | (84) | | | (125) | | — | | | — | | | | | | | | | | | | | | | Interest rate contracts: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income | | — | | | — | | | 2 | | | 2 | | | — | | | — | | | 6 | | | 6 | | | | | | | | | | | | | | | (Gain) or loss on fair value hedging relationships: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Interest rate contracts: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Hedged items | | — | | | — | | | 29 | | | (21) | | | — | | | — | | | 20 | | | (18) | | | | | | | | | | | | | | | Derivatives designated as hedging instruments | | — | | | — | | | (29) | | | 21 | | | — | | | — | | | (20) | | | 18 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Information regarding derivatives not designated as hedging instruments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (Gain) or loss on derivatives not designated as instruments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Foreign currency forward/option contracts | | — | | | 1 | | | (13) | | | 2 | | | 7 | | 6 | | | (7) | | | (11) | | | | | | | | | | | | | |
*For periods prior to the April 1, 2024 separation of Solventum, these include certain insignificant amounts attributable to discontinued operations.
|